BridgeBio Wins Appeal Over Eidos Deal, Ending Pension Fund Suit

BridgeBio Pharma Inc. is free of shareholder litigation over its $175 million buyout of Eidos Therapeutics Inc. after Delaware’s top court rejected self-dealing claims brought by a pension fund.

The state supreme court ruled Wednesday for BridgeBio and three former Eidos directors: BridgeBio founder Neil Kumar, a KKR & Co. partner who previously sat on BridgeBio’s board, and the former chief scientific officer of both companies. The decision upheld a ruling by a Delaware Chancery Court judge who threw the case out last year.

Palo Alto, Calif.-based BridgeBio, whose Nasdaq-listed shares have surged more than 300% this year, owned 63% ...